Suicide Prevention And Antidepressants

Main Category: Depression
Also Included In: Psychology / Psychiatry;  Clinical Trials / Drug Trials;  Conferences
Article Date: 09 Jul 2008 - 6:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Depression is the most important single factor predisposing to suicide, and more than half of all subjects completing suicide are known to have suffered from depression. Unfortunately, depression is still often untreated or undertreated, even after a suicide attempt. Antidepressive drugs represent the cornerstone of treatment of depressive patients. However, their role has become somewhat controversial over the last few years due to reports suggesting that antidepressants might, in a small subgroup of younger patients (recently estimated at 0.7% in clinical trials) actually worsen suicidal tendencies instead of alleviating them.

As a consequence, regulatory authorities in many countries have reconsidered their cost-benefit ratio. On the other hand, in many western countries, increasing use of antidepressants on the national and regional level correlates, as expected with declining suicide mortality, and in no country has an increase in suicides due to antidepressants been reported.

While there is no doubt that potential side effects of antidepressive medication concerning suicidal behaviour are a very serious issue, it is important to obtain a balanced view of all the clinical and epidemiological facts pertaining to the effect of antidepressive therapy in relation to suicidal behaviour.

Professor Erkki Isometsä, a renowned expert in psychiatric suicide research, will present the state of evidence and critically comment on the current discussion concerning this topic with regard to the role of antidepressive treatment in real-life clinical practice.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

Press conference on 29 August 2008 in Barcelona, Spain.

SPEAKER: Professor Erkki T. Isometsä, Institute of Clinical Medicine, Department of Psychiatry, University of Helsinki, Finland

Source: Sonja Mak
European College of Neuropsychopharmacology